Möchten Sie immer auf dem neuesten Stand bleiben?

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of...

Las Vegas, NV, March 17, 2026 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (Nasdaq: JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, announced...

Cycurion, Inc. Statement Regarding Unauthorized Press Release, Fabrication of Investor Relations Contact, and Related Market Activity – Litigation Counsel

Ontex Group NV today publishes its 2025 annual report and related documents.

David Namdar will transition from his role as CEO in accordance with the Board’s succession planningCompany continued to execute BNB digital asset treasury strategy, including opportunistic share...

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed...

New York, USA, March 16, 2026 (GLOBE NEWSWIRE) -- Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling...

CMD Generated $40.5 Million in Preliminary Unaudited 2025 Revenue, Representing 32% Year-Over-Year Growth Compared with CMD’s Full-Year 2024 Pro Forma Revenue, Which Reflects the Full Year of CMD...

CALGARY, Alberta, March 16, 2026 (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to announce that the Toronto Stock Exchange (“TSX”) has approved...